Physician profile
Debbie Singh
NPI 1912774886
$2,719.90
in general payments reported to CMS, 2019-2025
14 companies · $539 in 2025
The $539 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $2,180 · 2025: $539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,545 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,544.90 |
| Education | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $759.86 | 2024 | Lynparza |
| Merck Sharp & Dohme LLC | $249.54 | 2024 | Welireg, Keytruda |
| Genzyme Corporation | $227.27 | 2024-2025 | |
| Pfizer INC. | $223.69 | 2024-2025 | |
| Janssen Biotech, INC. | $220.00 | 2024 | Akeega, Erleada, Imbruvica |
| Gilead Sciences, INC. | $155.48 | 2024-2025 | Trodelvy |
| Novocure INC. | $148.84 | 2025 | Optune Lua (Novottf-200t) |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2025 | |
| Pharmaessentia USA Corporation | $125.00 | 2024 | Besremi |
| Abbvie INC. | $125.00 | 2024 | |
| Glaxosmithkline, LLC. | $122.10 | 2024 | Zejula |
| Genmab U.S., INC. | $117.56 | 2024 | Tivdak |
| Eisai INC. | $103.49 | 2024 | |
| Novartis Pharmaceuticals Corporation | $17.07 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debbie Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.